Search Within

Center for Hematologic Malignancies

Formats
  1. Journal Article (6195)
  2. Meeting Abstract (6166)
  3. Review (401)
  4. Book Section (216)
  5. Editorial (172)
  6. Research Letter (160)
  7. Guidelines (83)
  8. Conference Paper (70)
  9. Correspondence (61)
  10. Miscellaneous (19)
  11. Book Whole (10)
Groups
  1. Department of Medicine (11094)
  2. Hematologic Malignancies, Division of (10645)
  3. GSK Faculty (5449)
  4. Adult Leukemia (3723)
  5. Sloan Kettering Institute Faculty (3375)
  6. Hematologic Malignancies Research (3005)

More Groups

People
  1. Sergio Giralt (1069)
  2. Miguel-Angel Perales (946)
  3. Ross Levine (787)
  4. Andrew Zelenetz (785)
  5. Steven Horwitz (671)
  6. Martin Tallman (655)

More People

Years
  1. 2025 (317)
  2. 2024 (704)
  3. 2023 (877)
  4. 2022 (830)
  5. 2021 (802)
  6. 2020 (874)

More Years

Publications
  1. Blood (3413)
  2. Journal of Clinical Oncology (869)
  3. Biology of Blood and Marrow Transplantation (602)
  4. Clinical Lymphoma, Myeloma and Leukemia (304)
  5. Cancer Research (300)
  6. Haematologica (268)

More Publications

Publishers
  1. American Society of Hematology (3684)
  2. Elsevier Inc. (1669)
  3. Nature Publishing Group (1118)
  4. American Society of Clinical Oncology (918)
  5. American Association for Cancer Research (680)
  6. Wiley Blackwell (437)

More Publishers

Results (13553)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Results after long-term follow-up from the CAN2007 phase I/II study of weekly or twice-weekly bortezomib in patients (pts) with relapsed systemic light-chain (AL) amyloidosis
    Meeting Abstract

    Reece, D. E.; Hegenbart, U.; Sanchorawala, V.; Merlini, G.; Palladini, G.; Blade, J.; Fermand, J. P.; Hassoun, H.; Heffner, L.; Pei, L.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Infectious disease associations in advanced stage, indolent lymphoma (follicular, FL, and nonfollicular, nFL): A prospective trial of antibiotic therapy
    Meeting Abstract

    Portlock, C. S.; Hamlin, P. A.; Gerecitano, J. F.; Noy, A.; Palomba, M. L.; Walkley, J.; Corcoran, S.; Papanicolaou, G. A.; Markowitz, A.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Preliminary safety and efficacy of IPI-145, a potent inhibitor of phosphoinositide-3-kinase-δ,γ, in patients with relapsed/refractory CLL
    Meeting Abstract

    Patel, M. R.; Kahl, B. S.; Horwitz, S. M.; Younes, A.; Foss, F. M.; Oki, Y.; Sweeney, J.; Allen, K.; Faia, K.; Kelly, P. F.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A phase I study of ridaforolimus (MK-8669) in pediatric patients with advanced solid tumors
    Meeting Abstract

    Pearson, A. D. J.; Federico, S. M.; Aerts, I.; Hargrave, D. R.; DuBois, S. G.; Iannone, R.; Geschwindt, R.; Wang, R. X.; Trippett, T. M.; Geoerger, B.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Belinostat, a novel pan-histone deacetylase inhibitor (HDACi), in relapsed or refractory peripheral T-cell lymphoma (R/R PTCL): Results from the BELIEF trial
    Meeting Abstract

    O'Connor, O. A.; Masszi, T.; Savage, K. J.; Pinter-Brown, L. C.; Foss, F. M.; Popplewell, L.; Cashen, A. F.; Doorduijn, J.; Chawla, S.; Knoblauch, P.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A phase II study of the selective phosphatidylinositol 3-kinase delta (PI3Kδ) inhibitor idelalisib (GS-1101) in combination with rituximab (R) in treatment-naive patients (pts) ≥ 65 years with chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL)
    Meeting Abstract

    O'Brien, S. M.; Lamanna, N.; Kipps, T. J.; Flinn, I.; Zelenetz, A. D.; Burger, J. A.; Holes, L.; Johnson, D. M.; Gu, J.; Dansey, R. D.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Intraperitoneal radioimmunotherapy (RIT) for desmoplastic small round cell tumor (DSRCT): Initial results from a phase I trial
    Meeting Abstract

    Modak, S.; La Quaglia, M. P.; Carrasquillo, J. A.; Zanzonico, P.; Enero, C.; Pandit-Taskar, N.; Kang, H. J.; Cheung, N. K. V.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • Medical oncologists' clinical experiences and comfort levels with 20 recently approved agents
    Meeting Abstract

    Love, N.; Anderson, K. C.; Flaherty, K.; Kantarjian, H. M.; Lynch, T. J.; O'Shaughnessy, J.; Sartor, A. O.; Venook, A. P.; Zelenetz, A. D.; Moss, J.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A phase II study of mocetinostat, an oral isotype-selective histone deacetylase (HDAC) inhibitor, in combination with 5-azacitidine in patients with myelodysplastic syndrome (MDS)
    Meeting Abstract

    Luger, S. M.; O'Connell, C. L.; Klimek, V.; Cooper, M. A.; Besa, E. C.; Rossetti, J. M.; Reid, G. K.; Humphrey, R.; Martell, R. E.; Garcia-Manero, G.
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save
  • A phase II trial of radiation and cetuximab followed by irinotecan/cetuximab for children with newly diagnosed diffuse pontine tumors and high-grade astrocytomas
    Meeting Abstract

    Macy, M.; Kieran, M. W.; Chi, S. N.; Cohen, K. J.; MacDonald, T.; Smith, A. A.; Etzl, M. M.; Narendran, A.; Gore, L.; DiRenzo, J.; more...
    Journal of Clinical Oncology (2013)

    Fulltext@MSK | Save